Disc Medicine, Inc. — Director's Dealing 2021

Feb 10, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Gemini Therapeutics, Inc. /DE (GMTX)
CIK: 0001816736
Period of Report: 2021-02-05

Reporting Person: Lauder Scott (Chief Technology Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	104622	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$1.2846	2028-08-27	Common Stock (68354)		Direct
Stock Option (Right to Buy)	$2.5234	2030-03-10	Common Stock (16347)		Direct
Stock Option (Right to Buy)	$7.6160	2030-10-15	Common Stock (21136)		Direct

Footnotes

F1: Stock option to purchase common stock issued as merger consideration pursuant to the Agreement and Plan of Merger by and among Gemini Therapeutics Inc., FS Development Corp., FSG Merger Sub Inc. and Shareholder Representative Services LLC, dated as of October 15, 2020 (the "Merger Agreement"). This option shall vest and become exercisable in 16 equal quarterly installments commencing at the end of the three month period immediately following the Vesting Commencement Date, November 5, 2017; provided the Optionee continues to have a Service Relationship with the Company on each vesting date. Notwithstanding anything in the Agreement to the contrary, in the case of a Sale Event, this Stock Option and the Shares shall be treated as provided in Section 3(c) of the Plan; provided, however, 100% of the then-unvested Shares shall vest and be exercisable immediately upon a Sale Event.

F2: Stock option to purchase common stock issued as merger consideration pursuant to the Merger Agreement. This option shall vest and become exercisable over a period of four years from the Vesting Start Date, March 11, 2020 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

F3: Stock option to purchase common stock issued as merger consideration pursuant to the Merger Agreement. This option shall vest and become exercisable 25% shall vest on the one year anniversary of the Vesting Start Date, October 16, 2020, and the remainder shall vest over a period of 36 months thereafter, provided that as of each such vesting date the Grantee remains in a business relationship with the Company.